Inspire Medical: Temporary Disruptions Mask Solid Foundation; GLP-1 Risk Remains

What happened

Inspire Medical's stock has been pressured by a sharp revenue slowdown tied to temporary CPT coding changes and CMS Project WISeR disruptions, not a fundamental erosion of its business model. The company maintains a robust balance sheet with ~$400M in liquidity and no debt, providing downside protection and supporting a valuation near 1x EV/sales. Competitive threats from Nyxoah and GLP-1 therapies are deemed manageable, with IP litigation successes and the potential for GLP-1s to expand Inspire's addressable market by increasing OSA diagnosis. However, the DeepValue report emphasizes that GLP-1 competition and DOJ scrutiny remain structural risks, with a base case of 10-13% revenue growth and 84-86% gross margins. The stock's 51% decline over the past year reflects these headwinds, but the upcoming 2026 Medicare reimbursement uplift and Inspire V adoption could catalyze a recovery if execution improves.

Implication

Investors should weigh the attractive entry at $90-$100 against the risks of GLP-1 cannibalization and DOJ outcomes. Position sizing must account for a wide distribution of outcomes, with a 6-18 month horizon for the reimbursement catalyst to materialize. The lack of a margin of safety at current valuation requires strict monitoring of volume growth and margin trends.

Thesis delta

The market has overreacted to temporary coding disruptions, but the structural GLP-1 overhang remains unresolved. The thesis shifts from a high-growth story to a slower, high-margin grower dependent on the 2026 reimbursement uplift and execution on Inspire V. Without clear evidence of volume re-acceleration, the stock lacks a margin of safety.